<DOC>
	<DOC>NCT00409903</DOC>
	<brief_summary>We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and after activation of the sympathetic nervous system.</brief_summary>
	<brief_title>The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Eprosartan</mesh_term>
	<criteria>Both genders. Age 18 65 years. Body mass index less or equal to 30 kg/m2. Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal. History or clinical signs of heart, lung, kidney, or endocrine organ disease. Abnormal biochemical screening of the blood regarding: Bhemoglobin, Psodium, Ppotassium, Pcreatinine, Palbumin, Pbilirubin, Palanine aminotransferase, Palkaline phosphatase, Pcholesterol, and Bglucose. Abnormal screening of the urine regarding: albumin and glucose Malignant disease. Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic. Alcohol abuse. Smoking. Drug use or abuse. Known intolerance or allergy to eprosartan or sodium nitroprusside. Blood donation within 1 month of the start of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>